Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Antimicrob Agents Chemother ; 42(3): 606-11, 1998 Mar.
Article in English | MEDLINE | ID: mdl-9517940

ABSTRACT

Amphotericin B colloidal dispersion (ABCD) is a new formulation of conventional amphotericin B designed to minimize drug distribution in the kidney and reduce nephrotoxicity. We studied the safety and efficacy of ABCD in 133 renally compromised patients with invasive fungal infections. Patients had either nephrotoxicity from amphotericin B or preexisting renal disease. Intravenous treatment with ABCD (4 mg/kg of body weight daily) was administered for up to 6 weeks. Evaluations included clinical response to treatment and adverse events, with emphasis on changes in serum creatinine levels. ABCD did not appear to have an adverse effect on renal function: mean serum creatinine level tended to decrease slightly with days on therapy, and increases were not dose related. Complete or partial response to treatment was reported for 50% of the 133 intent-to-treat patients and 67% of the 58 evaluable patients.


Subject(s)
Amphotericin B/therapeutic use , Antifungal Agents/therapeutic use , Kidney/drug effects , Mycoses/drug therapy , Renal Insufficiency/complications , Adolescent , Adult , Aged , Aged, 80 and over , Amphotericin B/adverse effects , Antifungal Agents/adverse effects , Child , Child, Preschool , Female , Follow-Up Studies , Humans , Infant , Male , Middle Aged , Mycoses/etiology , Prospective Studies , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...